NervGen Pharma Appoints Experienced Biotech CFO Keith Vendola to Lead Financial Strategy
NGEN sits 18% above its 52-week low of $3.51.
Summary
NervGen Pharma Corp. has appointed Keith Vendola, MD, MBA, as its new Chief Financial Officer, effective immediately. Dr. Vendola brings over two decades of financial and strategic experience from clinical-stage biopharmaceutical companies, including leading IPOs and financial transformations. This leadership enhancement is significant as NervGen accelerates the clinical development of its lead candidate, NVG-291, towards a registrational study in chronic tetraplegia. His expertise in capital markets and corporate development will be crucial for managing the company's financial strategy and supporting its growth initiatives, which are vital for funding ongoing and future clinical trials.
At the time of this announcement, NGEN was trading at $4.14 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $317.2M. The 52-week trading range was $3.51 to $6.30. This news item was assessed with positive market sentiment and an importance score of 7 out of 10. Source: GlobeNewswire.